Reactions Weekly

, Volume 1732, Issue 1, pp 60–60 | Cite as


Treatmet failure secondary to drug resistance during hepatitis C treatment: 5 case reports
Case report
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a study of 239 patients conducted between November 2017−May 2018, five patients (four men and one woman) [ages at the time of reaction onset not clearly stated] were described, who exhibited treatment failure secondary to emergence of resistance to asunaprevir/daclatasvir, ledipasvir/sofosbuvir, elbasvir/grazoprevir or asunaprevir/beclabuvir/daclatasvir during treatment of hepatitis C virus (HCV) infection [routes, dosages and duration of treatment to reactions onsets not stated].

Case 1: The man exhibited treatment failure secondary to emergence of resistance to asunaprevir/daclatasvir and ledipasvir/sofosbuvir: The man with HCV genotype 1b, presented at the age of 50 years. He was admitted for the treatment of HCV owning to previous treatment failure of various direct...


  1. Akuta N, et al. Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct-acting antivirals regimens. Journal of Medical Virology 91: 102-106, No. 1, Jan 2019. Available from: URL: - JapanCrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations